EPO and myelodysplastic syndrome: These findings suggest that patients with LR-MDS who have low baseline hemoglobin levels, high serum EPO levels, or are transfusion-dependent at baseline could be identified prior to treatment and offered alternative, perhaps more beneficial, first-line therapies.